GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » 3-Year EPS without NRI Growth Rate

Tibet Aim Pharm (SZSE:002826) 3-Year EPS without NRI Growth Rate : 5.30% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm 3-Year EPS without NRI Growth Rate?

Tibet Aim Pharm's EPS without NRI for the three months ended in Mar. 2024 was ¥0.15.

During the past 12 months, Tibet Aim Pharm's average EPS without NRI Growth Rate was 2.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 5.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Tibet Aim Pharm was 30.50% per year. The lowest was -38.70% per year. And the median was -2.10% per year.


Competitive Comparison of Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate falls into.



Tibet Aim Pharm 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Tibet Aim Pharm  (SZSE:002826) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Tibet Aim Pharm 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines